Novartis | NOVN - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 5.57B 2.9B 2026-03
Alcon AG USD 240M 24M 2026-03
Almirall EUR 30.32M 22M 2025-12
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Autolus Therapeutics Ltd USD -91.52M 12.93M 2025-12
Bayer EUR -3.37B 2.21B 2025-12
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Fresenius EUR 601M 122M 2025-12
Fresenius Medical Care EUR 340M 168.46M 2026-03
Genmab DKK 55M 427M 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
GRIFOLS EUR 190.51M 20.03M 2025-06
Hikma Pharmaceutical USD 147.5M 3.5M 2025-06
J&J USD 7.82B 2.86B 2026-03
Lakefront Biotherapeutics EUR 13.96M 769.2M 2026-03
Lonza CHF 624M 197M 2024-12
Merck EUR 401M 886.1M 2025-12
Merck USD 3.42B 3.32B 2025-12
Novartis USD 3.84B 802M 2026-03
Novartis USD 5.17B 637M 2025-09
Novo Nordisk DKK 33.8B 3.23B 2025-06
Orion EUR 113.4M 213.6M 2026-03
Pfizer USD 5.18B 6.82B 2026-03
Philips EUR 466M 191M 2025-12
Recordati EUR 151.97M 7.02M 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
UCB EUR 789M 427M 2025-06